Ganglioside GM1 is a complex glycosphingolipid composed of a ceramide backbone linked to a branched pentasaccharide containing sialic acid, galactose, N-acetylgalactosamine, and glucose residues. It is a major structural and functional component of neuronal plasma membranes, playing critical roles in cell recognition, signaling, and neuroprotection. It functions as a high-affinity receptor for cholera toxin and similar bacterial toxins, mediates neuronal survival and differentiation, and is implicated in inherited and acquired neurological disorders. GM1 is widely studied for its therapeutic potential in neurodegenerative disease and neuronal repair and as a biomarker and drug target in neurology and infectious disease.
Acts as a binding receptor for cholera toxin and similar toxins, facilitating their entry and ADP-ribosylation mechanism. Modulates neuronal survival and regeneration through effects on neurotrophins and plasticity. Regulates membrane signaling by organizing protein complexes within lipid rafts. As a drug: Promotes neurorepair and inhibits neuronal apoptosis.
03
Biological functions
Cell-cell recognition and adhesionSignal transduction via lipid raftsPromote neuronal differentiation, survival, and regenerationModulate immune responseServe as a receptor for specific bacterial toxins (e.g., cholera toxin, heat-labile enterotoxin)Neuroprotective (regulate autophagy, inhibit neurodegeneration)
04
Disease associations
Neurodegenerative disease (GM1 gangliosidosis, Parkinson's disease)Inherited storage disease (GM1 gangliosidosis)Infection (site of action for cholera toxin, E. coli heat-labile enterotoxin, simian virus 40)Inflammatory neuropathy (Guillain–Barré syndrome, Multifocal Motor Neuropathy)DementiaOther: Used experimentally in spinal cord injury repair
05
Safety considerations
Risk of antibody-mediated inflammation with anti-GM1 antibodies (neuropathies)Potential accumulation toxicity (in gangliosidosis)Limited blood–brain barrier penetration and cost for use as a therapeutic agent
06
Interacting drugs
GM1 ganglioside itself is investigated as a therapeutic agent, particularly in neurodegenerative conditions and spinal cord injury
3 more in the full profile.
07
Biomarkers
Elevated GM1 in tissues or cerebrospinal fluid (biomarker for gangliosidosis, neurodegeneration)Anti-GM1 antibodies (biomarker for Guillain–Barré syndrome, Multifocal Motor Neuropathy)GM1 staining and detection as a neuronal marker
Beyond the preview
Go deeper on Ganglioside GM1 (GM1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Drug pipeline
Explore the programs pursuing this target and their development progress.
Drug candidates
Developers
Development stage
Clinical trials
Follow the clinical studies evaluating therapies directed at this target.
Trial design
Status
Readouts
Competitive landscape
Compare approaches across drug candidates, modalities, and indications.
Programs
Modalities
Indications
Literature & evidence
Investigate the research and source evidence behind target biology and development.
Publications
Sources
Analysis
Patents
Explore patent activity around therapies and technologies addressing this target.
Patents
Assignees
Technologies
Research & analysis
Connect target biology, drug development, and emerging evidence in your research.
Biology
Development news
Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ganglioside GM1 (GM1).